The authors assessed the efficacy and safety of lenalidomide plus rituximab in patients with untreated, advanced stage indolent non–Hodgkin lymphoma. Lenalidomide plus rituximab is well tolerated and highly active as initial treatment for indolent non–Hodgkin lymphoma. An international phase 3 study (NCT01476787) to compare this regimen with chemotherapy in patients with untreated follicular lymphoma is in progress.

READ FULL ARTICLE Curated publisher From Mdlinx